Key facts
- Revalesio’s last known valuation is $86.4M (Jul 2020).
- It has raised $112.8M across 6 recorded rounds; the latest was Early Stage VC ($38.9M) in May 2022.
- Notable investors include Cumming Capital Management, ALS.
- Revalesio has filed 7 Form Ds with the SEC since 2012, most recently Apr 2024 ($25.5M sold to 31 investors).
- Status: Privately Held (backing).
Investors
2- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Revalesio
Funding rounds
6 roundsAbout Revalesio
Developer of an anti-inflammatory therapeutic drug designed to treat a variety of neurological diseases. The company's drug targets mitochondrial dysfunction and inflammation by combining intense local turbulence to provide neuroprotection through large energy dissipation rates and surface-to-volume mixing ratios, enabling physicians to treat amyotrophic lateral sclerosis and multiple sclerosis by slowing down disease progression and improving quality of life.
- Sector
- Healthcare
- HQ
- Tacoma, WA, United States
- Founded
- 2000
- Employees
- 21
- Website
- revalesio.com/
- Ownership
- Privately Held (backing)
Revalesio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Revalesio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Revalesio in its N-PORT filings yet. We sweep new filings monthly.